// App-Quantinova.ai

POS08 : Zotarolimus-eluting vs. bare-metal stent in high bleeding risk patients undergoing a 30-day intended duration of dual antiplatelet therapy A pre-specified analysis from the Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS) study

Researchers

Presenter

  • Ariotti S

Principal Investigators

  • Costa F

  • Valgimigli M

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Angina

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • ZoMaxx

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved